Modified Parkinson's drug shows potential in treating nonalcoholic fatty liver disease

(GIST(Gwangju Institute of Science and Technology)) Nonalcoholic fatty liver disease (NAFLD) severely impairs the quality of life in patients and often leads to various liver complications. Recently, scientists at Gwangju Institute of Science and Technology designed a novel compound that can potentially treat NAFLD by targeting peripheral serotonin, which regulates lipid metabolism in the liver. They achieved this by structurally modifying an existing neurological drug such that it targets peripheral serotonin by minimizing brain penetration.
Source: EurekAlert! - Biology - Category: Biology Source Type: news